Global Medical Directory is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Overview rapifleX MALDI PharmaPulse - rapifleX MALDI PharmaPulse | Bruker
Connect with this vendor - Learn about this product

apifleX MALDI PharmaPulse ®

apifleX MALDI PharmaPulse ® - Accelerate uHTS with Mass Spectrometry The rapifleX MALDI PharmaPulse (MPP) accelerates label-free hit finding in drug discovery: rapifleX MPP combines the unambiguousness of mass spectrometry with the required speed to comb through large compound libraries of millions of substances. The use of mass spectrometry allows the measurement of unmodified substrates in primary screens to avoid false positives or false negatives, making confirmation screens redundant. The system is designed for fully automatic handling of 1536 sample plates to screen more than a million compounds in a week in support of drug discovery. Rapiflex MPP HighRes Biosolutions New standard for ultra-HTS Label-Free ‘Hit’ Identification By combining the speed of Bruker’s patented Smartbeam™ 3D laser technology with the direct-detection capability of mass spectrometry, the rapifleX MALDI PharmaPulse (MPP) delivers unprecedented screening capability for HTS biochemical assays. It allows you to screen through large and diverse compound libraries at a pace of over a million compounds a week, epitomizing the perfect balance of automation and miniaturization. The MPP system allows for the measurement of unmodified substrates in primary biochemical screens, and offers several advantages: It effectively eliminates confirmatory assays typically required of traditional fluorescence-based screening techniques Saves costs for developing specific fluorescence probes.